

Performance Against Time to Target

REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
13/LO/041	112763	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	Number Agreed	2	2	Date Agreed	31/10/2017	1	18/02/2016	1	Withdrawn By Host
14/SC/101	156913	CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	Number Agreed	2	2	Date Agreed	30/09/2015	4	08/01/2016	5	Recruitment Finished
14/YH/112	160884	EXTEND (2819MA1002)	Number Agreed	3	3	Date Agreed	28/02/2016	0	04/02/2016	0	Recruitment Finished
14/LO/149	158617	CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage IV Melanoma (CA209-172)	Number Agreed	3	3	Date Agreed	30/10/2015	3	18/01/2016	3	Recruitment Finished
15/LO/092	181642	SMTC11004: Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)	Number Agreed	1	1	Date Agreed	19/02/2016	1	18/02/2016	1	Recruitment Finished
15/LO/027	149700	M14-011: Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)	Number Agreed	8	8	Date Agreed	29/02/2016	1	18/03/2016	1	Recruitment Finished
15/SS/018	190856	Protocol 083: MK5172A + Sofosbuvir +/-RBV in Cirrhotic GT3 Subjects (MK-5172-083)	Number Agreed	6	6	Date Agreed	24/03/2016	4	24/03/2016	4	Recruitment Finished
15/EE/010	163708	MK5172/ MK3682 with MK8742 or MK8408 in HCV GT1, GT2, and GT4 Infected Subjects	Number Agreed	5	5	Date Agreed	01/02/2016	4	25/03/2016	4	Recruitment Finished
14/YH/126	160993	CHIL3644 I.V. Tapentadol in post op pain	Number Agreed	1	1	Date Agreed	30/06/2016	0	04/04/2016	0	Withdrawn By Host
15/NW/05	174966	CHIL4421 (NP25737)	Number Agreed	1	1	Date Agreed	30/01/2017	0	10/05/2016	0	Withdrawn By Sponsor
15/LO/069	174324	Checkmate - 171	Number Agreed	4	4	Date Agreed	01/04/2016	4	01/06/2016	8	Recruitment Finished
14/SC/131	155403	MCRN3165 (SD744) Cubist PSI Osteomyelitis	Number Agreed	3	3	Date Agreed	30/06/2016	0	09/06/2016	0	Recruitment Finished
15/SC/039	183591	An evaluation of the tolerance and acceptability of Neocate Junior, an amino acid based feed for children.	Number Agreed	3	3	Date Agreed	31/07/2016	2	31/07/2016	2	Recruitment Finished
15/LO/090	167412	630-0012 Pulmonx LIBERATE Study	Number Agreed	4	4	Date Agreed	31/10/2016	2	30/09/2016	2	Recruitment Finished
14/LO/179	161154	NCRN - 3312 - MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer	Number Agreed	4	4	Date Agreed	01/04/2016	2	05/01/2016	2	Withdrawn By Sponsor
13/YH/020	129722	Sativex Severe Spasticity	Number Agreed	6	6	Date Agreed	31/12/2015	5	01/07/2016	5	Recruitment Finished
13/LO/016	114841	MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305 (CCRN 2104)	Number Agreed	3	3	Date Agreed	01/10/2016	1	20/07/2016	1	Recruitment Finished
15/NW/06	185354	OKAH-193 Varicella vaccine study in the second year of life	Number Agreed	100	100	Date Agreed	31/07/2016	100	27/07/2016	100	Recruitment Finished

Performance Against Time to Target

14/SC/142	159287	GX29185	Number Agreed	7	7	Date Agreed	31/10/2016	7	28/07/2016	7	Recruitment Finished
15/YH/040	183603	Single Dose of MK0517 for Prevention of CINV in Paediatric Subjects	Number Agreed	4	4	Date Agreed	08/08/2016	0	03/08/2016	0	Withdrawn By Sponsor
15/LO/051	170613	CANC - 4281 - YOSEMITE	Number Agreed	5	5	Date Agreed	30/08/2016	1	08/08/2016	1	Recruitment Finished
13/NW/03	130144	MCRN234 (WA28118)	Number Agreed	2	2	Date Agreed	30/10/2016	2	10/08/2016	2	Recruitment Finished
15/EE/040	189187	DIAB 4501	Number Agreed	4	4	Date Agreed	15/08/2016	4	15/08/2016	4	Recruitment Finished
15/LO/041	171579	Safety and Efficacy of Brimonidine-DDS in patients with GA-AMD	Number Agreed	3	3	Date Agreed	31/08/2016	3	09/09/2016	3	Recruitment Finished
13/SC/000	118729	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma.	Number Agreed	5	5	Date Agreed	01/08/2016	4	28/09/2016	4	Recruitment Finished
16/HRA/01	198232	NEUTROPENIC SEPSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER	Number Agreed	18	18	Date Agreed	31/07/2016	22	31/07/2016	22	Recruitment Finished
15/LO/116	178877	Efficacy and Safety of RTH258 versus Aflibercept	Number Agreed	4	4	Date Agreed	26/04/2016	6	30/04/2016	6	Recruitment Finished
14/YH/103	149080	MCRN3102 (SD653) Grunenthal Tapentadol Acute/Postoperative Pain (KF65)	Number Agreed	4	4	Date Agreed	28/11/2016	1	13/10/2016	1	Withdrawn By Sponsor
12/SW/008	96688	LFG316 (CLFG316A2204)	Number Agreed	5	5	Date Agreed	30/11/2016	6	22/11/2016	6	Recruitment Finished
14/LO/161	159770	GLP110933 study Type I DM Study (DRN 3266)	Number Agreed	2	2	Date Agreed	18/11/2016	3	30/11/2016	2	Recruitment Finished
15/WA/03	184197	The TARGET All Comer Clinical Trial	Number Agreed	80	80	Date Agreed	16/12/2016	124	17/10/2016	124	Recruitment Finished
13/NW/00	114402	CCRN 1073 (Thoracic aortic surgery)	Number Agreed	15	15	Date Agreed	30/11/2016	22	30/11/2016	22	Recruitment Finished